TargetBeta
CD274
CD274 molecule · also B7-H, B7H1, PD-L1, PDL1 · CD molecules
19 programs in company-led studies act on CD274, from 15 companies: 12 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 14 programs
- Small Cell Lung Carcinoma, 5 programs
- Triple Negative Breast Neoplasms, 5 programs
- Colorectal Neoplasms, 4 programs
- Neoplasms, 4 programs
- Breast Neoplasms, 3 programs
- Endometrial Neoplasms, 3 programs
- Melanoma, 3 programs
- Neoplasm Metastasis, 3 programs
- Carcinoma, Hepatocellular, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 22, 2026Anti-PD-L1 Antibody-drug Conjugate HLX43 · Fosun Pharma · phase 3 · NCT06839066
- Nov 30, 2026durvalumab · AstraZeneca · phase 4 · NCT07081633
- Dec 2026adebrelimab · Jiangsu HengRui Medicine · phase 3 · NCT05482568
- Dec 2026Anti-PD-L1/4-1BB Bispecific Antibody LBL-024 · Nanjing Leads Biolabs · phase 3 · NCT05170958
- Jan 1, 2027pumitamig · BioNTech · phase 3 · NCT05879055
- Jan 1, 2027Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505 · China Resources Pharmaceutical Group · phase 2 · NCT06838546
- Jan 15, 2027sotiburafusp alfa · Huabo Biopharm · phase 3 · NCT07376629
- Mar 30, 2027HLX37 · Fosun Pharma · phase 3 · NCT07274813
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.